FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2037239145> ?p ?o ?g. }

• W2037239145 endingPage "51" @default.
• W2037239145 startingPage "41" @default.
• W2037239145 abstract "Zidovudine was used in an open uncontrolled study for treatment of 145 human immunodeficiency virus (HIV) patients, 102 with acquired immune deficiency syndrome (AIDS) and 43 with symptomatic HIV disease (acquired immune deficiency syndrome related-complex, ARC). The mean period of follow-up was 6 +/- 2.5 months. The median survival time of AIDS patients on zidovudine was 4.5 times longer when compared to a historical zidovudine untreated AIDS group (1657 vs. 370 days). This should be interpreted with reserve regarding improvements in treatment of all aspects of HIV infection and heightened awareness of AIDS which may have led to earlier diagnosis in the zidovudine treated groups. Pneumocystis carinii pneumonia (PCP) was very rarely a cause of death in zidovudine-treated patients (4.8%), while it was responsible for the death in 46.2% of historical controls (P less than 0.001). Extensive Kaposi's sarcoma was equally the cause of death in treated as well as in historical patients. Median T4 cell counts increased on zidovudine reaching a peak at the end of the fourth month of therapy in the ARC group and at the end of the first month in the AIDS group with a subsequent fall. Sixty per cent (53 of 87) patients were p24 viral antigen positive at the start of treatment and 19% of them had a fall of more than 50% in antigen level in three months while 32% became antigen negative within 2.5 months. Survival in patients where the antigen disappeared or in whom there was a major (greater than 50%) fall in antigen level was significantly higher than in those for whom there was no change in antigen level or in whom the antigen was negative at the start of the study (P less than 0.05). Forty-seven of the 145 zidovudine treated patients needed to be transfused because of anaemia. The mortality was significantly higher in this group of patients, particularly in those transfused prior to zidovudine therapy. Neutropenia occurred in four subjects. Platelets rose after the start of zidovudine but subsequently fell to thrombocytopenic levels in eight patients." @default.
• W2037239145 created "2016-06-24" @default.
• W2037239145 creator A5034644839 @default.
• W2037239145 creator A5044206468 @default.
• W2037239145 creator A5047262874 @default.
• W2037239145 date "1989-01-01" @default.
• W2037239145 modified "2023-10-14" @default.
• W2037239145 title "Zidovudine treatment of patients with acquired immune deficiency syndrome and acquired immune deficiency syndrome-related complex: St stephen's hospital experience" @default.
• W2037239145 cites W1970402671 @default.
• W2037239145 cites W2020975582 @default.
• W2037239145 cites W2333399282 @default.
• W2037239145 cites W3041047318 @default.
• W2037239145 cites W4256221661 @default.
• W2037239145 doi "https://doi.org/10.1016/s0163-4453(89)80079-9" @default.
• W2037239145 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/2492585" @default.
• W2037239145 hasPublicationYear "1989" @default.
• W2037239145 type Work @default.
• W2037239145 sameAs 2037239145 @default.
• W2037239145 citedByCount "10" @default.
• W2037239145 countsByYear W20372391452019 @default.
• W2037239145 crossrefType "journal-article" @default.
• W2037239145 hasAuthorship W2037239145A5034644839 @default.
• W2037239145 hasAuthorship W2037239145A5044206468 @default.
• W2037239145 hasAuthorship W2037239145A5047262874 @default.
• W2037239145 hasConcept C126322002 @default.
• W2037239145 hasConcept C187212893 @default.
• W2037239145 hasConcept C203014093 @default.
• W2037239145 hasConcept C2777914695 @default.
• W2037239145 hasConcept C2779127605 @default.
• W2037239145 hasConcept C2780216070 @default.
• W2037239145 hasConcept C2780727368 @default.
• W2037239145 hasConcept C3013748606 @default.
• W2037239145 hasConcept C71924100 @default.
• W2037239145 hasConcept C8891405 @default.
• W2037239145 hasConceptScore W2037239145C126322002 @default.
• W2037239145 hasConceptScore W2037239145C187212893 @default.
• W2037239145 hasConceptScore W2037239145C203014093 @default.
• W2037239145 hasConceptScore W2037239145C2777914695 @default.
• W2037239145 hasConceptScore W2037239145C2779127605 @default.
• W2037239145 hasConceptScore W2037239145C2780216070 @default.
• W2037239145 hasConceptScore W2037239145C2780727368 @default.
• W2037239145 hasConceptScore W2037239145C3013748606 @default.
• W2037239145 hasConceptScore W2037239145C71924100 @default.
• W2037239145 hasConceptScore W2037239145C8891405 @default.
• W2037239145 hasLocation W20372391451 @default.
• W2037239145 hasLocation W20372391452 @default.
• W2037239145 hasOpenAccess W2037239145 @default.
• W2037239145 hasPrimaryLocation W20372391451 @default.
• W2037239145 hasRelatedWork W2010288878 @default.
• W2037239145 hasRelatedWork W2010916963 @default.
• W2037239145 hasRelatedWork W2037239145 @default.
• W2037239145 hasRelatedWork W2038674059 @default.
• W2037239145 hasRelatedWork W2042218694 @default.
• W2037239145 hasRelatedWork W2055733835 @default.
• W2037239145 hasRelatedWork W2066920818 @default.
• W2037239145 hasRelatedWork W2089218908 @default.
• W2037239145 hasRelatedWork W2138360450 @default.
• W2037239145 hasRelatedWork W2410274077 @default.
• W2037239145 hasVolume "18" @default.
• W2037239145 isParatext "false" @default.
• W2037239145 isRetracted "false" @default.
• W2037239145 magId "2037239145" @default.
• W2037239145 workType "article" @default.